Save the date for the DIA/PREFER patient preferences workshop 15-16 June!

2021-04-15

Patient preferences can give us information that is critical for developing medical treatments. But they can also tell us how much risk patients think is acceptable for a given benefit. The pharmaceutical industry, regulatory authorities, HTA bodies, reimbursement agencies and patient organisations all agree that ‘patient preferences’ need to be part of decision making on benefit and risk. But how? When? And what are the regulatory requirements for preference studies? Join us online on 15-16 June to find out!

DIA/IMI PREFER patient preferences workshop 15-16 June 2021

PREFER is a public-private collaborative research project under the Innovative Medicines Initiative (IMI). Our mission is to find out what the key stakeholders think is important in order to be able to establish recommendations to support the development of guidelines for industry, Regulatory Authorities and HTA bodies on how and when to include patient perspectives on benefits and risks of medicinal products.

The workshop is organised for the first time as a collaboration between DIA and IMI PREFER. During the workshop we will discuss:

  • How to decide how and when to include patients’ perspectives on benefits and risks of medicinal products.
  • The value of patient preference studies and navigate through various frameworks and methods for conducting these studies.
  • The broad variety of stakeholders present will provide a wide range of perspectives concerning Patient Preference studies and their inclusion in regulatory decision making.

Find out more & register

The programme committee includes

  • Antonella Cadone, President, European Cancer Patient Coalition (ECPC)
  • John Bridges, Professor, Departments of Biomedical Informatics and Surgery, Ohio State University College of Medicine, USA
  • Jürgen Kübler, Owner, Quantitative Scientific Consulting, Germany
  • Mireille Muller, Regulatory Policy & Intelligence Director, Novartis Pharma AG, Switzerland
  • Sara Torgal, Scientific Programmes Manager, DIA EMEA